Esperion to Report Fourth Quarter and Full Year 2021 Financial Results February 22, 2022
Esperion (NASDAQ: ESPR) will announce its fourth quarter and full year 2021 financial results on February 22, 2022, before the U.S. market opens. The company will conduct a webcast and conference call at 8:00 a.m. ET to discuss the results and business progress, accessible via phone or on their website. Esperion focuses on innovating cholesterol-lowering medications, including NEXLETOL® and NEXLIZET® tablets, aimed primarily at patients inadequately served by existing treatments.
- Scheduled financial results announcement may indicate positive performance.
- Company's focus on innovative cholesterol-lowering therapies addresses unmet patient needs.
- None.
ANN ARBOR, Mich., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2021 financial results before the open of the U.S. financial markets on Tuesday, February 22, 2022.
Following the release, company management will host a webcast and conference call at 8:00 a.m. ET to discuss financial results and business progress. The call can be accessed by dialing (877) 831-3840 (domestic) or (253) 237-1184 (international) five minutes prior to the start of the call and providing the access code 7349619.
A live audio webcast can be accessed on the investor and media section of the Esperion website at investor.esperion.com. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
ESPERION Therapeutics
Esperion works hard to make our medicines easy to get, easy to take and easy to have. We discover, develop and commercialize innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren’t being met by the status quo. Our entrepreneurial team of industry leaders is inclusive, passionate and resourceful. We are singularly focused on managing cholesterol so you can improve your health easily. Esperion commercializes NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Tablets and is the leader in the development of convenient oral, once-daily non-statin LDL-cholesterol lowering drugs for patients with high levels of bad cholesterol. For more information, please visit www.esperion.com and follow us on Twitter at www.twitter.com/EsperionInc.
Investor Contact:
Kaitlyn Brosco
Esperion
corporateteam@esperion.com
FAQ
When will Esperion report its financial results?
What time is the conference call for Esperion's financial results?
How can I access Esperion's financial results webcast?
What medications does Esperion specialize in?
What is the ticker symbol for Esperion?
